NCT06916455

Brief Summary

The long-chain polyunsaturated fatty acids (PUFA) of the n-3 or omega-3 series and, in particular, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both derived from the essential fatty acid alpha-linolenic acid, are part of all cell membranes and from them derive numerous compounds such as prostaglandins, thromboxanes, leukotrienes, resolvins, protectins and maresins that play numerous biological roles, most notably in the control of body homeostasis, blood coagulation and inflammation. The omega-3 index is a biomarker that reflects the nutritional status of n-3 PUFA, as well as cardiometabolic risk and cardiovascular health. This index is determined as the sum of the percentages in weight of EPA and DHA over the total of fatty acids present in the erythrocyte membranes. Previous studies carried out in Spain, such as ANIBES, indicate that in adults, and especially in those over 60 years of age, the intake of n-3 PUFA is well below the international recommendations, which is directly related to a low intake of fish, since both EPA and DHA are abundant in oily fish. However, in Spain, the nutritional status of omega-3 PUFA and their possible association with a higher prevalence of cardiometabolic risk is unknown, as well as the relationships with food intake and the cultural and socioeconomic status of the population. Therefore, the main objective of the present study is to evaluate the omega-3 index in the Spanish population over 60 years of age and to establish whether there are differences by sex, as well as in the different Spanish communities. In addition, we will study the possible associations between the omega-3 index and food intake, particularly of fish and omega-3 PUFA-rich supplements, as well as their possible associations with cardiometabolic risk indicators and cultural and socioeconomic conditions of the population. Determination of the omega-3 index usually requires an invasive venous blood collection followed by processing for separation of erythrocytes and extraction and methylation of their membrane lipids followed by chromatographic analysis. But fatty acids can also be determined on whole blood using less invasive methods, such as obtaining drops of blood with a lancet and depositing them on chromatographic paper impregnated with an antioxidant (dried spots). All this makes sampling much easier, although the result of the omega-3 index has to be corrected because it is affected by the lipid composition present in the plasma. For this reason, this project aims to carry out a validation study between the results of the fatty acid profile obtained in erythrocytes and in whole blood in the Spanish population (medamediantedried spots). In short, the results obtained will be used to calculate regression lines that allow us to evaluate the omega-3 index in erythrocytes in the adult Spanish population from different regions of Spain by means of a minimally invasive methodology. For this purpose, 800 participants aged 60 years or more will be recruited from different regions of Spain, randomized by age and sex for each region; at least 100 of the total number of participants should be frequent consumers of omega-3 supplements; if this figure is not obtained, an active search will be carried out until this number is reached (booster). All of them will be interviewed to complete different questionnaires on cultural and socioeconomic status, history of metabolic disease and cardiovascular health, and questionnaires on frequency of consumption and food intake reminders as established by the European Union. With the help of health personnel from different pharmacies and in mutual agreement with the General Council of Pharmaceutical Associations of Spain, a whole blood sample will be taken by lancet, which will be used to quantify the omega-3 index. For the validation study it will be necessary to obtain whole venous blood extracted by venipuncture from a subsample of 200 participants. This sample will be processed and will be used to determine the fatty acid profile in whole blood and in erythrocytes, which will be related by means of multiple linear and bivariate regression models with the fatty acid profile obtained in the dried spots. Cardiometabolic risk markers will also be determined in these 200 subjects, which will be used to establish relationships with the calculated omega-3 status.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
8mo left

Started Mar 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress64%
Mar 2025Dec 2026

Study Start

First participant enrolled

March 19, 2025

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

March 31, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 8, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2026

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

April 11, 2025

Status Verified

April 1, 2025

Enrollment Period

1.1 years

First QC Date

March 31, 2025

Last Update Submit

April 8, 2025

Conditions

Keywords

erythrocyte omega-3 fatty acidspopulation over 60 years of agenutritional statuscardiovascular risk

Outcome Measures

Primary Outcomes (1)

  • omega-3 index

    The omega-3 index measure the presence of omega-3 fatty acids in the erythrocyte membrane

    At the time of enrollement

Secondary Outcomes (8)

  • Nutritional assesment

    At the time of enrollement

  • Physical activity assesment

    At the time of enrollement

  • Socioeconomic assesment

    At the time of enrollement

  • DNA genotyping

    At the time of enrollement

  • Plasma triacylglycerides

    At the time of enrollement

  • +3 more secondary outcomes

Study Arms (2)

Validation cohort

Healthy people (n=200) over 60 year of age that will be bleeded for the validation of the dry spot methodology

Exploratory cohort

Healthy people (n=600) over 60 year of age that will be study with the dry spot methodology

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

800 volunteers in total, men and women from 37 locations in Spain distributed in 8 different areas (Nielsen Areas) covering the eastern, eastern, eastern, southern, southern, central, northwestern, northern and metropolitan areas of Madrid and Barcelona in Spain. These 800 participants will be randomized according to sex and the territory to which they belong, into three age groups: one group will be between 60 and 70 years old, another group will be between 71 and 80 years old, and the third will be made up of people over 80 years old. In addition, 100 of these subjects must be regular consumers of omega-3 supplements.

You may qualify if:

  • Older than 60 years of age

You may not qualify if:

  • Gastrointestinal diseases that affect the absorption of nutrites
  • Cancer
  • Chronic kidney disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Avd del Conocimiento 19

Granada, Granada, 18016, Spain

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood, plasma, erythrocytes, white blood cells

Study Officials

  • Estefanía Sánchez Rodríguez, PhD

    Universidad de Granada

    PRINCIPAL INVESTIGATOR

Central Study Contacts

María D Mesa García, PhD

CONTACT

Carolina T Gómez Llorente, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Proffesor

Study Record Dates

First Submitted

March 31, 2025

First Posted

April 8, 2025

Study Start

March 19, 2025

Primary Completion

April 30, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

April 11, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will share

all collected anonimous IPD

Shared Documents
STUDY PROTOCOL
Time Frame
Beginning 1 year after publication with no end date
Access Criteria
A proposal that describes planned analyses must be submitted, and a data sharing agreement must be signed. Researcher will contact the IP of tthe present project (estefaniasr@ugr.es), explain the proposal. She will send them an agreement document to be submitted.

Locations